Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM707 ± pembrolizumab in advanced or metastatic solid tumors
2022-503060-33-00Phase 2Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of NGM707 in Non-hematologic malignancy, Pulmonary squamous cell carcinoma, Non-small cell lung cancer adenocarcinoma (NSCLC) and 1 more (5 arms), sponsored by NGM Biopharmaceuticals. Primary endpoints: Treatment-emergent adverse events and Objective response rate (ORR). Started Jul 2023; status: completed.
02
Drugs
NGM707
03
Conditions
Non-hematologic malignancyPulmonary squamous cell carcinomaNon-small cell lung cancer adenocarcinoma (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-503060-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503060-33-00.